1-(4-Oxo-1-pyridin-3-ylmethyl-3,4-dihydro-phthalazin-6-yl)-3-p-tolyl-urea | 497255-74-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 1-(4-Oxo-1-pyridin-3-ylmethyl-3,4-dihydro-phthalazin-6-yl)-3-p-tolyl-urea
• 英文别名: 1-(4-methylphenyl)-3-[4-oxo-1-(pyridin-3-ylmethyl)-3H-phthalazin-6-yl]urea
• CAS: 497255-74-0
• 化学式: C₂₂H₁₉N₅O₂
• 分子量: 385.425
• InChiKey: UCCDAQPBXOYNQZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  29
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  95.5
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  4-{3-Methoxy-4-[1-(4-oxo-1-pyridin-3-ylmethyl-3,4-dihydro-phthalazin-6-yl)-3-p-tolyl-ureidomethyl]-phenoxy}-N-(4-methyl-benzyl)-butyramide 、 三氟乙酸 以 二氯甲烷 为溶剂， 反应 2.0h， 以yielding 11 mg of title compound的产率得到1-(4-Oxo-1-pyridin-3-ylmethyl-3,4-dihydro-phthalazin-6-yl)-3-p-tolyl-urea
  参考文献：
  名称：

  Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them

  摘要：

  本文披露了按照公式1的氨基-酞嗪酮衍生物及其医药上可接受的盐，以及包含它们的制药组合物；这些化合物或组合物对于治疗由于和/或与蛋白激酶活性改变有关的疾病，如癌症、细胞增殖性疾病、阿尔茨海默病、病毒感染、自身免疫性疾病和神经退行性疾病具有用处。

  公开号：

  US07432263B2

文献信息

• AMINO-PHTHALAZINONE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
  申请人：Pharmacia Italia S.p.A.

  公开号：EP1427708A1

  公开（公告）日：2004-06-16
• AMINO-PHTHALAZINONE DERIVATIVES AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
  申请人：Pfizer Italia S.r.l.

  公开号：EP1427708B1

  公开（公告）日：2008-09-10
• US7432263B2
  申请人：——

  公开号：US7432263B2

  公开（公告）日：2008-10-07
• [EN] AMINO-PHTHALAZINONE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM<br/>[FR] DERIVES D'AMINO-PHTALAZINONE ACTIFS COMME INHIBITEURS DE KINASE, PROCESSUS DE PREPARATION ET COMPOSITIONS PHARMACEUTIQUES CONTENANT CES DERIVES
  申请人：PHARMACIA ITALIA SPA

  公开号：WO2003014090A1

  公开（公告）日：2003-02-20

  Compounds which are amino-phthalazinone derivatives according to formula 1 and pharmaceutically acceptable salts thereof, togetherwith pharmaceutical compositions comprising them are disclosed; these compounds or compostions are useful in the treatment of diseases caused by and/or associated with an altered protein kinase activity such as cancer, cell proliferative disorders, Alzheimer'sdisease, viral infections, autoimmune diseases and neurodegenerative disorders.